Methods for collagen processing and products using processed collagen

• US 9,056,151 B2
• Filed: 02/12/2007
• Issued: 06/16/2015
• Est. Priority Date: 02/12/2007
• Status: Active Grant

• Current Assignee: Warsaw Orthopedic Incorporated (Medtronic Plc)
• Original Assignee: Warsaw Orthopedic Incorporated (Medtronic Plc)
• Inventors: Lauritzen, Nels J., Shimp, Lawrence A.
• Primary Examiner(s): Bradley, Christina
• Application Number:
  US11/673,972
• Publication Number:
  US 20080195202A1
• Time in Patent Office: 3,046 Days
• US Class Current: 1/1
• CPC Class Codes: A61L 15/325 Collagen
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 27/24 Collagen
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence

Abstract

Purifying human derived collagen from human tissue includes treating harvested human tissue with an enzyme to form a collagen product, deactivating the enzyme with a non-alkaline enzyme deactivation solution, and collecting the collagen product resulting from the enzyme treatment, where the collected collagen product includes a preserved amount of its natural collagen constituents. Various medical implants can be formed using the isolated, enzymatically-treated human derived collagen having an amount of its natural collagen constituents preserved, and may include implantable sponges, patches, tubes, structural supports and coatings, and which may be used for repair, barrier, support and/or stabilization purposes.

Claims

1. A medical implant comprising isolated, enzymatically-treated human derived collagen having a preserved amount of its natural collagen constituents, wherein the enzyme treatment comprises digesting the collagen with ficin and deactivating the ficin with a non-alkaline sodium chlorite solution to maintain growth factors and morphogenic proteins otherwise stripped away by exposure to an alkaline solution, wherein the collagen is lyophilized by exposing the collagen to a vapor phase cross-linking agent, the cross-linking agent comprising at least one of acetaldehyde, dialdehyde starch, glycerol polyglycidyl ethers, polyethylene glycol diglycidyl ethers, polyvalent metallic oxides, or a combination thereof, wherein the collagen comprises cartilage fragments, a plasticizer and angiogenesis promoting factors, the angiogenesis promoting factors comprising SEMA3.

2. The medical implant of claim 1, wherein the collagen is fibrillar human derived collagen.

3. The medical implant of claim 1, wherein the collagen is particulate human derived collagen.

4. The medical implant of claim 1, wherein said implant comprises a wound repair matrix.

5. The medical implant of claim 1, wherein said implant comprises an absorbent hemostat.

6. The medical implant of claim 1, wherein said implant comprises a medical repair patch.

7. The medical implant of claim 6, wherein the medical repair patch is a woven patch.

8. The medical implant of claim 6, wherein the medical repair patch is a non-woven patch.

9. The medical implant of claim 6, wherein the medical repair patch is a braided patch.

10. The medical implant of claim 6, wherein the medical repair patch is a film patch.

11. The medical implant of claim 6, wherein the medical repair patch is a knitted patch.

12. The medical implant of claim 6, wherein the medical repair patch is at least two of a woven, a non-woven, a braided, a film, and a knitted patch.

13. The medical implant of claim 1, wherein said implant comprises a vascular graft.

14. The medical implant of claim 1, wherein said implant comprises a neural graft.

15. The medical implant of claim 1, wherein said implant comprises a sphincter repair matrix.

16. The medical implant of claim 1, wherein said implant comprises a film.

17. The medical implant of claim 1, wherein said implant comprises a prosthetic having a coating of the enzymatically-treated human derived collagen.

18. The medical implant of claim 1, wherein said implant comprises an implantable instrument having a coating of the enzymatically-treated human derived collagen.

19. The medical implant of claim 1, wherein said implant comprises a structural support sling.

20. The medical implant of claim 1, wherein said implant comprises a bioactive agent.

21. A medical implant comprising:

reconstituted human derived collagen, wherein the human derived collagen comprises a preserved amount of its native collagen constituents of growth factors and morphogenic proteins, wherein the collagen is lyophilized by exposing the collagen to a vapor phase cross-linking agent, the cross-linking agent comprising at least one of acetaldehyde, dialdehyde starch, glycerol polyglycidyl ethers, polyethylene glycol diglycidyl ethers, polyvalent metallic oxides, or a combination thereof, wherein the collagen comprises cartilage fragments, a plasticizer and angiogenesis promoting factors, the angiogenesis promoting factors comprising SEMA3, and the medical implant comprises a cartilage repair structure.